Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Pembrolizumab (Keytruda) and immunotherapy

. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.

← All drugs · Search the portal

Facts

Topic Fact Source (access date)
First approval US 4 Sep 2014 (Merck Sharp & Dohme); EU 17 Jul 2015; China 25 Jul 2018 (melanoma) Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125514 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); https://www.bjcancer.org.cn/Html/News/Articles/8768.html (4 Nov 2026)
Mechanism Humanised antibody binding PD-1 and blocking PD-L1 and PD-L2; PD-1 is a negative regulator of T cell activity eMC SmPC https://www.medicines.org.uk/emc/product/2498/smpc (accessed 4 Nov 2026)
Use in osteosarcoma Trials only. US accelerated approvals for MSI-high/dMMR solid tumours (23 May 2017) and TMB-high solid tumours (16 Jun 2020) are not osteosarcoma-specific. UK SmPC: KEYNOTE-051 children's trial (161 patients, 6.2% osteosarcoma), response 5.8% in solid tumours and lymphoma FDA archived page https://web.archive.org/web/20190423133424/https:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm (accessed 4 Nov 2026); https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/2498/smpc (accessed 4 Nov 2026)
Results SARC028: 1 of 22 osteosarcoma responded (5%). Other immunotherapy: HER2 CAR T, 17 evaluable, no responses; B7-H3 CAR T, HS-20093, trastuzumab deruxtecan trials recruiting, no results doi:10.1016/S1470-2045(17)30624-1; doi:10.1200/JCO.2014.58.0225; Level 2 facts (3 Nov 2026)
Side effects Immune-related: thyroid problems, pneumonitis, colitis, hepatitis, skin reactions, kidney inflammation eMC SmPC https://www.medicines.org.uk/emc/product/2498/smpc (accessed 4 Nov 2026)
Owner Merck & Co (MSD outside US and Canada). Subcutaneous Keytruda Qlex approved by FDA 19 Sep 2025 Drugs@FDA BLA125514 (accessed 4 Nov 2026); FDA, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection (accessed 4 Nov 2026)
Regulatory US, EU, UK, China: many cancers. Not osteosarcoma entries.json (portal export), sources opened 31 Oct to 3 Nov 2026

Hypotheses and open points (not established fact)